A Prospective Single-Arm Clinical Trial of BCMA/CD3 BsAb Therapy for POEMS Syndrome
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a prospective, single-arm, investigator-initiated clinical trial evaluating the safety and efficacy of a BCMA/CD3 bispecific antibody (CM336) in patients with POEMS syndrome.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 78
Healthy Volunteers: f
View:
• Age ≥ 18 years.
• Diagnosed with POEMS syndrome according to the 2025 Chinese Expert Consensus.
• Deemed suitable for BCMA/CD3 bispecific antibody therapy by the investigator.
• ECOG performance status 0-2.
• Adequate organ function.
• Provided written informed consent.
Locations
Other Locations
China
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
RECRUITING
Tianjin
Contact Information
Primary
Gang An, MD
angang@ihcams.ac.cn
13502181109
Time Frame
Start Date: 2025-08-04
Estimated Completion Date: 2027-12-01
Participants
Target number of participants: 10
Treatments
Experimental: BsAbs-treatment group
Related Therapeutic Areas
Sponsors
Leads: Institute of Hematology & Blood Diseases Hospital, China